2020 Faculty Research Poster Session and Research Fair
Permalink for this collection. Use this when sharing or citing this source:https://hdl.handle.net/11310/276
Browse
Browsing 2020 Faculty Research Poster Session and Research Fair by Author "Bos, Tasia J."
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item Inhibition of Sorcin Protein to Improve the Efficacy of Doxorubicin in the Treatment of Metastatic Breast Cancer(WTAMU Cornette Library, 2020-03-05) Muniz, Alexandra E.; Phelps, Shelby M.; Bos, Tasia J.; Yarbrough, Jason C.; Khan, David R.Doxorubicin, and the liposomal formulation Doxil, are among the first-line chemotherapeutic agents used in the treatment of a variety of cancers, including metastatic breast cancer. Although doxorubicin has proven to be an effective cytotoxic agent, one major challenge in current therapy is the development of cancer cell resistance to this drug. One possible mechanism by which this resistance can occur is through overexpression of the calcium-binding protein, sorcin, which has the potential to directly bind doxorubicin, thereby limiting its cytotoxic effects. Therefore, the focus of this research is to utilize the compound dihydromyricetin (DMY), a known inhibitor of sorcin to potentially increase the overall efficacy of doxorubicin. In this study, a series of cytotoxicity assays were conducted to assess cytotoxic effect of doxorubicin against metastatic breast cancer cells (MDA-MB-231) as well as non-cancerous breast cells (MCF-10A), both with and without the inhibitor. A significant increase in cytotoxic capabilities of doxorubicin was observed in the metastatic cell line when coupled with DMY. Furthermore, western blot analysis was used to probe for the overexpression of sorcin in both non-cancerous breast cells as well as the metastatic cell line. Future work will involve the incorporation of doxorubicin and DMY into a unique, targeted-liposomal formulation which will ultimately be tested in cytotoxicity assays.